AXSM

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM - Research Report) yesterday and set a price target of $80.00. The company's shares closed yesterday at $57.23.Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Intra-Cellular Therapies, and Bioxcel Therapeutics. According to TipRanks, Suvannavejh has an average return of 0.0% and a 49.59% success rate on recommended stocks. In addition to Mizuho Securities, Axsome Therapeutics also received a Buy from SVB Securities's Marc Goodman in a report issued on November 14. However, on November 8, Morgan Stanley maintained a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).
https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-axsome-therapeutics-axsm-2?utm_source=advfn.com&utm_medium=referral